SARS-CoV-2 (AY.4/BA.1) Spike-pseudovirus was prepared by co-transfecting 293T cells with an HIV-1 backbone plasmid and a plasmid containing the SARS-CoV-2 (AY.4/BA.1) spike encoding gene. The packaged Spike-pseudovirus expresses full-length spike protein on the surface and carries a luciferase and GFP reporter gene, which can be used to infect cells that overexpress ACE2, and express luciferase and GFP in the cells to characterize infectivity of the virus.
Product Type
Pseudovirus
Target
SARS-CoV-2
Contents
SARS-CoV-2 (AY.4/BA.1) Spike full-length gene.
Backbone
Lentiviral vector
Reporter Gene
Luc/GFP
Variant
AY.4/BA.1
Applications
Neutralizing antibody / serum test / As a standard for ELISA and other tests.
Storage
Store at -20°C to -80°C
Introduction
The 2019 novel coronavirus, or "SARS-CoV-2", was discovered because of Wuhan virus pneumonia cases in 2019, and was named by the World Health Organization on January 12, 2020. It belongs to the beta genera of the Coronaviridae family, together with SARS coronavirus in 2003 and MERS coronavirus in 2012. The alignment between SARS-CoV-2 and 2003 SARS CoV has about 70% sequence similarity and 40% sequence similarity with MERS CoV. The coronavirus genome encodes a spike protein, an envelope protein, a membrane protein, and a nucleoprotein. Among them, spike protein is the most important surface membrane protein of coronavirus.